Veeva Systems today announced that Regeneron Pharmaceuticals has committed to Veeva Vault CRM globally. With Vault CRM, Regeneron plans to generate Commercial Evidence from AI-powered field engagement, uncovering hidden barriers to treatment adoption and ensuring their medicines can reach eligible patients in need.
Leading biopharma company Regeneron has selected Veeva Vault CRM to generate Commercial Evidence from field engagement. The platform will give commercial teams a more connected platform and faster access to information needed for efficient decision-making, helping ensure medicines can reach eligible patients in need.
Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution. With the Agentic Call Report in Vault CRM, every field interaction becomes a source of Commercial Evidence, capturing insights previously lost to dropdowns and compliance concerns.
"We are pleased to expand our strategic partnership with Veeva by moving to Vault CRM, which will give our commercial teams a more connected platform and help them get faster access to the information they need for efficient decision-making," said Ryan Steinberger, executive vice president and chief digital and technology officer at Regeneron.
"Regeneron uses the power of science to invent, develop, and commercialize life-transforming medicines for people with serious diseases," said Matt Farrell, president, commercial strategy at Veeva. "We are honored to extend our strategic partnership with Regeneron to include Veeva Vault CRM as they continue to deliver important new medicines to people in need."
The adoption underscores the growing demand for agentic CRM solutions in life sciences that combine AI-powered engagement, compliance-ready reporting, and actionable commercial insights to overcome treatment adoption barriers.
About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.
